Pyoderma

MolecuLight Featured in 11 Presentations and Posters at European Wound Management Association (EWMA) 2024 Annual Conference

Retrieved on: 
Wednesday, May 1, 2024
Enhanced, Health equity, Publication, DX, Collection, Health Canada, Conference, Research, Pyoderma, Workflow, Detection, Patient, European Wound Management Association, EWMA, Quality of life, Medical imaging

TORONTO and LONDON, May 1, 2024 /PRNewswire/ - MolecuLight Inc. , the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association (EWMA) 2024 Annual Conference, being held from May 1 - 3, 2024 in London, United Kingdom.

Key Points: 
  • TORONTO and LONDON, May 1, 2024 /PRNewswire/ - MolecuLight Inc. , the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association (EWMA) 2024 Annual Conference, being held from May 1 - 3, 2024 in London, United Kingdom.
  • The annual EWMA meeting is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.
  • "The impressive collection of at least 11 talks and posters from multiple and diverse facilities globally shows how the MolecuLight imaging device is becoming a new standard-of-care in this specialty.
  • A selection of the clinical posters and presentation featuring the MolecuLight i:X and DX from European Wound Management Association (EWMA) 2024 Annual Conference are as follows:
    (a)  Select Clinical Presentations and Workshops citing the MolecuLight point-of-care devices include:
    Presentation on MolecuLight by Dr. Jonathan Johnson
    Does bacterial fluorescence imaging improve chronic wound biofilm detection over standard clinical assessment and blotting?

MolecuLight Featured in 11 Presentations and Posters at European Wound Management Association (EWMA) 2024 Annual Conference

Retrieved on: 
Wednesday, May 1, 2024
Enhanced, Health equity, Publication, DX, Collection, Health Canada, Conference, Research, Pyoderma, Workflow, Detection, Patient, European Wound Management Association, EWMA, Quality of life, Medical imaging

TORONTO and LONDON, May 1, 2024 /PRNewswire/ -- MolecuLight Inc., the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association (EWMA) 2024 Annual Conference, being held from May 1 - 3, 2024 in London, United Kingdom. The annual EWMA meeting is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.

Key Points: 
  • TORONTO and LONDON, May 1, 2024 /PRNewswire/ -- MolecuLight Inc. , the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association (EWMA) 2024 Annual Conference, being held from May 1 - 3, 2024 in London, United Kingdom.
  • The annual EWMA meeting is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.
  • "The impressive collection of at least 11 talks and posters from multiple and diverse facilities globally shows how the MolecuLight imaging device is becoming a new standard-of-care in this specialty.
  • A selection of the clinical posters and presentation featuring the MolecuLight i:X and DX from European Wound Management Association (EWMA) 2024 Annual Conference are as follows:
    (a)  Select Clinical Presentations and Workshops citing the MolecuLight point-of-care devices include:
    Presentation on MolecuLight by Dr. Jonathan Johnson
    Does bacterial fluorescence imaging improve chronic wound biofilm detection over standard clinical assessment and blotting?

InflaRx Appoints Jan Medina as Head of Investor Relations

Retrieved on: 
Thursday, February 22, 2024
Therapy, Capital market, Research, CFA, Proteomics, Hematology, Biomedicine, Pyoderma, Biomedical engineering, Receptor (biochemistry), Pharmaceutical industry

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.

Key Points: 
  • JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.
  • Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research.
  • Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We are delighted to welcome Jan to our team.
  • Jan joins InflaRx from Olink Proteomics where he was Vice President, Investor Relations & Capital Markets.

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Retrieved on: 
Monday, November 6, 2023
FDA, Arm, Multinational, Food, Therapy, PG, Biotechnology, MD, European Medicines Agency, Ulcer, OD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clutch (eggs), Phase, EMA, Phase III offensive, Safety, Patient, Pyoderma, Neutrophil, Pharmaceutical industry

“We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum.

Key Points: 
  • “We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum.
  • In both arms, corticosteroid treatment will be initiated on day 1 and will be tapered off within the first 8 weeks of the trial.
  • The primary endpoint of the study is complete closure of the target ulcer at any time up to 26 weeks after initiation of treatment.
  • The enrollment period is projected to last at least two years, and its overall period will depend on the total trial size after sample size adaptation.

InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

Retrieved on: 
Tuesday, April 4, 2023
EUA, Vaccine, Sepsis, IMV, Therapy, C5a, The Lancet, Conference call, Extracorporeal membrane oxygenation, European Medicines Agency, COVID-19, Survival, ECMO, European Directive on Traditional Herbal Medicinal Products, EDT, Intensive care medicine, Dexamethasone, EMA, Hospital, Emergency Use Authorization, Patient, Standard of care, CEST, Mortality, Marketing Authorisation Application, Pyoderma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, News, Conference, Food, CHMP, Pharmaceutical industry, Perfume

PANAMO is one of the largest 1:1 randomized, double-blind placebo-controlled trials in invasively mechanically ventilated COVID-19 patients in intensive care units.

Key Points: 
  • PANAMO is one of the largest 1:1 randomized, double-blind placebo-controlled trials in invasively mechanically ventilated COVID-19 patients in intensive care units.
  • A total of 369 patients were randomly assigned to the vilobelimab treatment group (six 800-mg infusions) or the placebo group.
  • InflaRx continues discussions with FDA related to submission of a BLA for full approval of Gohibic in this COVID-19 indication.
  • The Company is assessing all options for supplying drug to hospitals to enable the treatment of patients.

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

Retrieved on: 
Wednesday, December 21, 2022
STS, Food, Pyoderma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Inflammation, Jean-Louis Vincent, NMPA, USD, C5a, Patient, Immortalised cell line, FDA, Therapy, Sale, Pharmaceutical industry, Security (finance)

Through the amendment of the existing co-development agreement, InflaRx will receive royalties of 10% on net sales of BDB-001 for the treatment of COVID-19 in China.

Key Points: 
  • Through the amendment of the existing co-development agreement, InflaRx will receive royalties of 10% on net sales of BDB-001 for the treatment of COVID-19 in China.
  • The existing co-development agreement contains an exclusive license restricted to development and commercialization within the territory of China and was granted to STS by InflaRx in 2015.
  • STS is now planning to apply for regulatory approval in China of BDB-001 for the treatment of COVID-19.
  • The option for such subsequent purchase will expire on the twelve-month anniversary of STS receiving regulatory approval for BDB-001 in China.

Global Monoclonal Antibodies in Veterinary Health Market Report to 2030 - Featuring Bayer Animal Health, Boehringer Ingelheim, Elanco and Indian Immunologicals Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, November 11, 2022
Health, Veterinary, Other Health, Dog, Animal, Prevalence, Cancer, Dermatitis, Otitis, USD, Awareness, Application, PETS, Allergy, Neutralizing antibody, Pyoderma, Atopic dermatitis, COVID-19, Industry, Vaccine

The "Monoclonal Antibodies in Veterinary Health Market Share, Size, Trends, Industry Analysis Report, By Animal Type, By Application, By End-Use, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoclonal Antibodies in Veterinary Health Market Share, Size, Trends, Industry Analysis Report, By Animal Type, By Application, By End-Use, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to this new study, the global monoclonal antibodies in veterinary health market size is expected to reach USD 2,629.6 million by 2030.
  • The report gives a detailed insight into current market dynamics and provides an analysis of future market growth.
  • Additionally, it is anticipated that awareness of advanced veterinary therapeutic options is likely to complement market growth.

InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Retrieved on: 
Thursday, September 29, 2022
Autoimmunity, EUA, Therapy, Accelerated approval (FDA), COVID-19, Federation, Jean-Louis Vincent, Receptor (biochemistry), FDA, Blood, Complement, Review, Manifest and latent functions and dysfunctions, Pyoderma, End organ damage, Program, Patient, CEO, The Lancet, Vaccine, Nasdaq, Founder, White Light Rock & Roll Review, Fast Track, Priority review, Death, C5a, US Food Sovereignty Alliance, Sepsis, Inflammation, GLOBE, Mortality, Pharmaceutical industry

Additionally, InflaRx has been granted Fast Track designation from the FDA for vilobelimab for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients.

Key Points: 
  • Additionally, InflaRx has been granted Fast Track designation from the FDA for vilobelimab for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients.
  • Prof. Niels C. Riedemann, CEO and Founder of InflaRx, said: The EUA submission is an exciting milestone for InflaRx in the development of our lead candidate, vilobelimab.
  • We believe that the data from our Phase III study strongly support the potential of vilobelimab to reduce the number of deaths in critically ill, invasively mechanically ventilated COVID-19 patients.
  • We look forward to working with the FDA on the review of our application with the goal of making vilobelimab available to patients in need.

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Retrieved on: 
Tuesday, July 26, 2022
End organ damage, Inflammation, GLOBE, Mortality, Receptor (biochemistry), CEO, COVID-19, Manifest and latent functions and dysfunctions, EUA, C5a, US Food Sovereignty Alliance, Complement, FDA, Pyoderma, Patient, Blood, Nasdaq, Jean-Louis Vincent, Therapy, Autoimmunity, Federation, Founder, Pharmaceutical industry

As previously announced, the company had requested the meeting to discuss a potential EUA submission and the development of its first-in-class anti-C5a monoclonal antibody vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients.

Key Points: 
  • As previously announced, the company had requested the meeting to discuss a potential EUA submission and the development of its first-in-class anti-C5a monoclonal antibody vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients.
  • In the meeting with the FDA, the company discussed in detail the completed Phase III part of the PANAMO study in invasively mechanically ventilated, critically ill COVID-19 patients.
  • The company also obtained guidance from the agency on deliverables related to its planned submission for EUA.
  • InflaRx also committed to additional discussions with the agency regarding its further development of vilobelimab for critically ill invasively mechanically ventilated COVID-19 patients.

InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

Retrieved on: 
Wednesday, July 6, 2022
Review, C5a, FDA, Autoimmunity, Priority review, Patient, European Medicines Agency, CEO, PGA, GLOBE, Biomarker, Orphan drug, COVID-19, Blood, Company, Division, White Light Rock & Roll Review, Plasma, Complement, Biologics license application, Fast Track, EMA, Food, Receptor (biochemistry), Therapy, Observation, Founder, Communication, Pyoderma, Inflammation, Nasdaq, New Drug Application, Plasma protein binding, US Food Sovereignty Alliance, Accelerated approval (FDA), BLA, PG, NDA, Collection, Pharmaceutical industry, Medical device, Dermatology

JENA, Germany, July 06, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that the US Food and Drug Administration (FDA) granted a Fast Track designation to the development of its first-in-class anti-C5a monoclonal antibody vilobelimab for the treatment of ulcerative pyoderma gangrenosum (PG).

Key Points: 
  • JENA, Germany, July 06, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that the US Food and Drug Administration (FDA) granted a Fast Track designation to the development of its first-in-class anti-C5a monoclonal antibody vilobelimab for the treatment of ulcerative pyoderma gangrenosum (PG).
  • The Company had submitted a request for Fast Track designation to the FDA on the positive outcome data in PG from its Phase IIa open-label dose-escalation study.
  • We are pleased that our development in pyoderma gangrenosum has been designated Fast Track by the FDA shortly after receiving the Orphan Drug designation, recognizing PG as serious condition with high unmet medical need and vilobelimab as promising potential future treatment option, said Prof. Niels C. Riedemann, CEO and Founder of InflaRx.
  • Fast track is a process designed by the FDA to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.